Transcatheter valve-in-valve replacement for degenerated mitral bioprostheses was associated with similar 30-day and one-year mortality rates as redo surgical mitral valve replacement (SMVR) in a retrospective study, despite the former being performed in older, sicker patients.

Mutations in the CHD4 gene are known contributors to congenital heart defects. Biologists at the University of North Carolina School of Medicine believe they are beginning to understand why.

An investigational transcatheter mitral valve replacement (TMVR) device helped reduce mitral regurgitation to zero or trace levels in 98.7 percent of patients, according to 30-day follow-up data from the first 100 people scheduled to be treated with Abbott’s Tendyne system.

Despite being performed in an older population with more cardiovascular comorbidities, transcatheter aortic valve replacement (TAVR) demonstrated similarly low rates of postoperative stroke and mortality compared with surgical aortic valve replacement (SAVR) in a study of patients with previous strokes.

Although survival after congenital heart surgery is improving, patients who receive procedures for even mild defects have long-term mortality rates at least three times higher than their counterparts in the general population, according to a U.S.-based registry study published in the Journal of the American College of Cardiology.

Acetaminophen after pediatric heart surgery was associated with an increasingly protective effect against acute kidney injury (AKI), according to an analysis of separate cohorts at two children’s hospitals.

The first patient to be treated with a novel mitral valve repair system is recovering and showed no complications during a 30-day follow-up period, according to a press release issued by the system's developer.

Edwards Lifesciences has received CE mark approval for its Cardioband Tricuspid Valve Reconstruction System, making it the first commercially available transcatheter therapy to treat tricuspid valve heart disease.